Clinical Research Papers:
Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy
Metrics: PDF 1862 views | HTML 2652 views | ?
Wanqi Zhu1, Li Jia3, Guanxuan Chen2, Hanxi Zhao1, Xiaorong Sun4, Xiangjiao Meng1, Xianguang Zhao1, Ligang Xing1, Jinming Yu1,2, Meizhu Zheng2
1Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, Shandong, China
2Shandong Key Laboratory of Radiation Oncology, Jinan, Shandong, China
3Department of Radiation Oncology, Jinan Fourth People’s Hospital, Jinan, Shandong, China
4Department of Radiology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, Shandong, China
Hanxi Zhao, email: [email protected]
Ligang Xing, email: [email protected]
Keywords: epigallocatechin-3-gallate, breast neoplasms, dermatitis, radiation
Received: December 21, 2015 Accepted: May 04, 2016 Published: May 20, 2016
There are few effective treatment options for radiation-induced dermatitis in breast cancer patients. We conducted a single-arm trial to tested the hypothesis that topical epigallocatechin-3-gallate (EGCG) is effective against radiation-induced dermatitis in breast cancer patients undergoing radiotherapy. Forty-nine patients participated in this study. The patients underwent mastectomy followed by adjuvant radiotherapy. Topical EGCG was applied daily, starting when grade I dermatitis appeared and ending two weeks after radiotherapy. The maximum dermatitis observed during the EGCG treatment was as follows: Grade 1 toxicity, 71.4% (35 patients); grade 2 toxicity, 28.6% (14 patients); there were no patients with grade 3 or 4 toxicity. The majority of the radiation-induced dermatitis was observed 1 week after the end of radiotherapy. EGCG reduced the pain in 85.7% of patients, burning-feeling in 89.8%, itching in 87.8%, pulling in 71.4%, and tenderness in 79.6%. These findings suggest topical EGCG may be an effective treatment for radiation-induced dermatitis and has acceptable toxicity.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.